Emerging data in platinum resistance advanced ovarian cancer-Recording

Video Transcription

Video Summary

In this IGCS webinar, Dr. David O'Malley and Dr. Lainey Martin discuss emerging data on platinum-resistant advanced ovarian cancer. They emphasize the importance of early testing for biomarkers like folate receptor alpha and HRD, helping guide treatment decisions. The focus is on using therapies like Mirvotuximab soravtansine (MIRV) in patients with high folate receptor alpha expression, even in less than 75% cases. They discuss the efficacy, tolerability, and management of potential side effects, particularly eye toxicity. The discussion also highlights the use of maintenance therapy, including Bevacizumab, and the importance of global access to testing and treatments. This informative session underscores the need for personalized approaches to optimize patient care.

Keywords

IGCS webinar

Dr. David O'Malley

Dr. Lainey Martin

platinum-resistant advanced ovarian cancer

biomarkers

Mirvotuximab soravtansine